In accordance with the publicity guidelines, press releases referring to the offering were added to Median Technologies’ website regular press release list on Sept. 21, 2023, i.e. more than 40 calendar days following the determination by the CEO acting upon delegation of the board of directors of the Company of the price for the shares to be issued by the Company in the Offering. Press releases referring to the Offering are now available without a special screening mechanism that restricts persons resident in restricted countries from accessing press releases.
Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit